Dr. Colombo on the Next Steps With Pembrolizumab in Cervical Cancer

Video

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Nicoletta Colombo, MD, PhD, associate professor, obstetrics and gynecology, University of Milan-Bicocca, director, Ovarian Cancer Centre, chair, Program of Gynecology, European Institute of Oncology, discusses the next steps with pembrolizumab (Keytruda) in cervical cancer.

On October 13, 2021, the FDA approved pembrolizumab in combination with chemotherapy with or without bevacizumab (Avastin) for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 per a combined positive score (CPS) of at least 1. The regulatory decision was based on findings from the phase 3 KEYNOTE-826 trial (NCT03635567), in which pembrolizumab plus chemotherapy with or without bevacizumab led to a statistically significant improvement in overall survival and progression-free survival vs placebo plus chemotherapy with or without bevacizumab in patients whose tumors have a PD-L1 CPS of 1 or higher.

As such, pembrolizumab should be considered a new standard of care for women with persistent, recurrent, or metastatic cervical cancer, Colombo explains. Now, pembrolizumab is being evaluated in earlier lines of treatment. The ongoing phase 3 KEYNOTE-A18 trial (NCT04221945) is evaluating chemoradiation with or without pembrolizumab in patients with locally advanced cervical cancer, Colombo explains.

Additionally, other PD-1/PD-L1 inhibitors are being evaluated in this patient population, Colombo concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,